ライフサイエンスコーパス: anti-HAV

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 ren in group 1 born to anti-HAV-negative and anti-HAV-positive mothers, respectively, and 4% of group

2 Although unexplained mechanistically, both anti-HAV antibody and inactivated whole-virus vaccines p

3 When examined by 5-year birth cohorts, anti-HAV prevalence increased in children born between 1

4 ith compensated liver disease had detectable anti-HAV antibody compared with 37.1% with decompensated

5 26 adults tested at 8-9 years had detectable anti-HAV.

6 n 94% of all vaccinees were seropositive for anti-HAV after the complete vaccination course.

7 Eighty-four anti-HAV antibody-negative patients, 49 with compensated

8 Of the 391 patients, 205 (52%) had anti-HAV IgG antibodies.

9 age-adjusted prevalence of antibody to HAV (anti-HAV) was 51% in 1983 and 49% in 1993 (P=.506).

10 V RNA at baseline was associated with higher anti-HAV antibody titers after the second vaccine dose.

11 Postvaccination IgG anti-HAV were determined at 1, 6, and 7 months after the

12 ining 105 children, immunization resulted in anti-HAV levels of 17-572 mIU/mL.

13 t age 6 months (50%-75%), and among maternal anti-HAV-positive children in groups 2 and 3 (67%-87%),

14 h group, infants were randomized by maternal anti-HAV status.

15 10 years regardless of presence of maternal anti-HAV.

16 r significantly by vaccine group or maternal anti-HAV status.

17 each group randomized according to maternal anti-HAV status.

18 al antibodies to hepatitis A virus (maternal anti-HAV) may lower the infant's immune response to the

19 cted hepatitis A subclinically (>8000 mIU/mL anti-HAV).

20 assay, while reciprocal GMTs of neutralizing anti-HAV were 6.5 and 15.0 by an 80% radioimmunofocus in

21 int, a lower geometric mean concentration of anti-HAV was observed for each group of CLD patients com

22 The GMC of anti-HAV antibody at week 48 for three-dose HIV-infected

23 The geometric mean concentration (GMC) of anti-HAV antibody was determined at weeks 48 and 72.

24 The geometric mean titers (GMTs) of anti-HAV were 49.3 and 45.2 mIU/mL by immunoassay, while

25 ng elicited an average 29.7-fold increase of anti-HAV levels.

26 We obtained levels of anti-HAV at intervals through age 15-16 years among thre

27 10 years of age correlated with initial peak anti-HAV levels (tested at 1 month after the second dose

28 was measured by qualitative and quantitative anti-HAV antibody measurements 1 month after each vaccin

29 Seropositivity (anti-HAV >/=20 mIU/mL) 30 years after the second vaccine

30 years, all children retained seroprotective anti-HAV levels except for only 7% and 11% of children i

31 Nonetheless, the model indicated that anti-HAV seropositivity should persist for >/=30 years a

32 ly 7% and 11% of children in group 1 born to anti-HAV-negative and anti-HAV-positive mothers, respect

33 At 10 years, children born to anti-HAV-negative mothers in group 3 had the highest geo

34 ectively, and 4% of group 3 children born to anti-HAV-negative mothers.

35 nterval, 71-133 mIU/mL) and children born to anti-HAV-positive mothers in group 1 had the lowest GMC

36 y indirect immunofluorescence analysis using anti-HAV monoclonal antibodies.

37 re tested for antibody to hepatitis A virus (anti-HAV) by ELISA.

38 rred maternal antibody to hepatitis A virus (anti-HAV) on the duration of seropositivity after hepati

39 Antibodies to hepatitis A virus (anti-HAV) were measured in children from two separate va

40 The presenting features of 29 adults with anti-HAV IgM positive ALF enrolled in the ALFSG_between

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。